Posted on August 30, 2007 by Albin Paul
IDENTIGENE Becomes First DNA Testing Lab to Promise Fast Results with a Money-Back Guarantee . The company now Now Offers the Industry’s First Money-Back Guarantee, together with a Three-Day Turnaround on Results
the website says IDENTIGENE is the only DNA testing lab with a money-back guarantee
Filed under: bioinformatics blog, clinical genomics, DNA, DNA diagnostics, DNA testing, gene expression, genetic testing, microarray blog | 2 Comments »
Posted on August 30, 2007 by Albin Paul
Scientists from the Lucile Packard Children’s Hospital and the Stanford University School of Medicine have identified a pattern of gene expression shared by a small group of patients who beat the odds and remained healthy for years without medication, after undergoing Organ transplant.
The findings made by Minnie Sarwal, MD, PhD, a pediatric nephrologist at Packard Children’s is a major advantage in organ transplantation treatment. Transplant recipients who share the same pattern of genes but are still on conventional medication may be able to reduce or eliminate their lifelong dependence on immunosuppressive drugs. The study may also help physicians determine how best to induce acceptance, or tolerance, of donor organs in all transplant patients, regardless of their gene expression profiles.
Although the anti-rejection medications, known as immunosuppressants, tamp down the immune system enough to permit lifesaving organ transplants, their benefits come at a price. They also quash the body’s natural response to dangerous invaders, such as bacteria and viruses, and to rogue cancer cells. Transplant physicians prescribing immunosuppressants to their patients walk a fine line between avoiding organ rejection and increasing the risk of infection and cancer
The researchers used microarray, or gene chip, technology to compare gene expression patterns in blood samples from 16 healthy volunteers with those from three groups of adult kidney transplant recipients from the United States, Canada and France
Filed under: biodefense, bioinformatics blog, cancer, clinical genomics, DNA, DNA diagnostics, gene expression, gene therapy, genetic medicine, genetics, Genomics, microaray blog, Pharmacogenomics, transgenomics | 24 Comments »
Posted on August 23, 2007 by Albin Paul
THe Haifa Lab of IBM provides the Technlogy for Clinicalgenomics and leads the research in lifesciences fieds.
The Clinica, Genomics division plans to provide technology to integrate clinial genomics data and HL7 and other complaince protocls followed in clinical research and clinia, trial and integrate them to provide better and focused clinical trials
Clinical genomics for biopharmaceuticals from IBM
the main advatages as per IBM website is that
- Encapsulate raw genomic data into an HL7 Clinical Genomics message, including transformation services of proprietary data formats to standardized formats like MAGE and BSML
- Access patient’s clinical history stored in an enterprise EHR system
- Access all major ontologies that provide genotype-phenotype relationships like OMIM, PharmGKB, etc.
- Parse the encapsulated raw genomic data and bubble-up selected genomic data items based on ontological knowledge as well as the patient clinical data
- Compare two Genotypes (the data model at the heart of the HL7 specs) in order to provide case-based reasoning services to decision support application that will use CGL7 as a specialized clinical genomics middleware
- Find a similar pedigree in case base of pedigrees in order to support risk assessment applications that base their assessment on family history
Filed under: bioinformatics, clinical genomics, clinical microarray, DNA, DNA diagnostics, gene expression, gene therapy, genetics, microarray blog, Pharmacogenomics, Theranostics | Leave a comment »
Posted on July 31, 2007 by Albin Paul
CombiMatrix announced that the DoD has awarded a one-year, $2.2 mln contract to CombiMatrix for further development of its microarray technologies for a multipathogen- and chemical-detection system.
Filed under: DNA, DNA diagnostics, DNA therapeutics, microarray, microarray blog | Leave a comment »
Posted on July 5, 2007 by Albin Paul
The average human gene consists of 3000 bases, but sizes vary greatly, with the largest known human gene being dystrophin at 2.4 million bases. Residing at Chromosome 4 it has long been of interest to the medical community because its the gene responsible for huntington’s disease, polycystic kidney disease, a form of muscular dystrophy and a variety of other inherited disorders. Chromosome 2 is noteworthy for being the second largest human chromosome, trailing only chromosome 1 in size. It is also home to the gene with the longest known, protein-coding sequence – a 280,000 base pair gene that codes for a muscle protein, called titin, which is 33,000 amino acids long.
Now reseacrhers at Emory university has developed a microarray based test to chek for mutations in this gene. The current test do not detect all types of mutation that affects 1 in 3500 males according to the university wesbite.
Mutations in the dystrophin such as point mutations in a sequence of DNA can result in mistakes in gene expression and nonfunctional proteins that causes Duchenne muscular dystrophy (DMD).
A detailed presentation of the advantages of the test is available at the Emory Genetics Testing website. The test offeredon the Nimblegen CGH array platform gains more prominance as the company is now being acquired by Roche who has plans to dominate the clinical microarray market with its products in genetics testing space
The emory university Genetics testing lab offers numerous other genetic tests
Filed under: clinical diagnostics, clinical microarray, DNA diagnostics, gene expression, genetic medicine, genetic testing, microarray blog, microarray for clinical diagnostics, Pharmacogenomics | 7 Comments »
Posted on June 23, 2007 by Albin Paul
I have been busy lately but found some time to go through an interesting story and a good article published in scientist magazine
- Father-in-law of now-infamous extensively drug-resistant TB patient studies tuberculosis at the CDC, and is now under review by the agency
- Genotyping with PCR -How to choose the right approach
I am working on an article about consolidation in Microarray and Bioinformatics industry so interesting to know about GenoLogics Announces Bioinformatics Partnership with Illumina so is the news of Roche acquiring Nimblgen and the end of patent wars with Affymetrix, Roche has also acquired 454 life sciences, It seems Roche plans to get inot clinical genomcis and theranostics application industry, the company already has FDA approved amplichip CYP450 arrays for clinical diagnostics
With many other acquisitions in the last one year and many more in the pipeline it seems paydays for early starters.
Filed under: bioinformatics blog, clinical diagnostics, clinical microarray, diagnostic microarray, DNA diagnostics, DNA medicine, microarray blog, microarray business, personalized medicine, Theranostics | Leave a comment »
Posted on June 7, 2007 by Albin Paul
Imagine a diabetic patient from NewYork being put on a drug regimen distinct from a patient London. Personalized medicine allows tratement to decided on the genetic make up of the individual. Genetically europeans and asians and others have different ways of responding to same treatment genetically
FortunatelyIf Indian researchers have their way, such customised medication based on genetic differences could be a possibility for a range of illnesses.
A consortium of Indian scientists recently completed a genetic database for India, home to one of the world’s most ethnically diverse populations that will allow researchers to understand the genetic predisposition of ethnic groups to diseases. Icelanders are considered for Human genome project because of very less number such diversity
The genetic map will enable global and Indian pharma companies to enhance research on predictive medicine and targeted drugs. Research firm TCG Life Sciences is about to become the first private player to use the database.
The consortium collected data on the genetic codes of over a 1,000 genes from among 15,000 individuals belonging to Indian sub-populations
Another user of the data is the clinical diabetics’ consortium, which aims to identify if there are specific genetic reasons for a particular ethnic group to be predisposed to the disease. It is already known that some cultures are pre disposed to certain diseases so Indian are more prone to heart attack and diabetes and such
The Indian Genome Variation Consortium, a public-private partnership that networks six Council of Indian Scientific and Industrial Research labs and some private software firms, undertook the genetic variation mapping.
Filed under: clinical diagnostics, DNA database, DNA diagnostics, DNA therapeutics, gene expression, gene therapy, genetic medicine, genetics, genotyping, microarray blog, personalized medicine, Pharmacogenomics | 7 Comments »